Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 660

The DOI matches its Crossref record; 118 of the 118 references it cites were found in a registry or an index.

Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC

Open access
Rolfo, Christian, Mack, Philip C., Scagliotti, Giorgio V., Baas, Paul, Barlesi, Fabrice, Bivona, Trever G., Herbst, Roy S., Mok, Tony S., Peled, Nir, Pirker, Robert, Raez, Luis E., Reck, Martin, Riess, Jonathan W., Sequist, Lecia V., Shepherd, Frances A., Sholl, Lynette M., Tan, Daniel S.W., Wakelee, Heather A., Wistuba, Ignacio I., Wynes, Murry W., Carbone, David P., Hirsch, Fred R., Gandara, David R.·2018·Journal of Thoracic Oncology

Abstract

ABSTRACT The isolation and analysis of circulating cell‐free tumor DNA in plasma is a powerful tool with considerable potential to improve clinical outcomes across multiple cancer types, including NSCLC. Assays of this nature that use blood as opposed to tumor samples are frequently referred to as liquid biopsies. An increasing number of innovative platforms have been recently developed that improve not only the fidelity of the molecular analysis but also the number of tests performed on a single specimen. Circulating tumor DNA assays for detection of both EGFR sensitizing and resistance mutations have already entered clinical practice and many other molecular tests — such as detection of resistance mutations for Anaplastic Lymphoma Kinase (ALK) receptor tyrosine kinase rearrangements — are likely to do so in the near future. Due to an abundance of new evidence, an appraisal was warranted to review strengths and weaknesses, to describe what is already in clinical practice and what has yet to be implemented, and to highlight areas in need of further investigation. A multidisciplinary panel of experts in the field of thoracic oncology with interest and expertise in liquid biopsy and molecular pathology was convened by the International Association for the Study of Lung Cancer to evaluate current available evidence with the aim of producing a set of recommendations for the use of liquid biopsy for molecular analysis in guiding the clinical management of advanced NSCLC patients as well as identifying unmet needs. In summary, the panel concluded that liquid biopsy approaches have significant potential to improve patient care, and immediate implementation in the clinic is justified in a number of therapeutic settings relevant to NSCLC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2018.05.030

Cites

118 of 118 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 118 references

Cited by

See all 660

Metadata

Authors
Rolfo, C., Mack, P. C., Scagliotti, G. V., Baas, P., Barlesi, F., Bivona, T. G., Herbst, R. S., Mok, T. S., Peled, N., Pirker, R., Raez, L. E., Reck, M., Riess, J. W., Sequist, L. V., Shepherd, F. A., Sholl, L. M., Tan, D. S. W., Wakelee, H. A., Wistuba, I. I., Wynes, M. W., Carbone, D. P., Hirsch, F. R., & Gandara, D. R.
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2018-09
Volume
13
Issue
9
Pages
1248-1268
ISSN
1556-0864 (ISSN-L)
OpenAlex
W2807519281
Cited by
660
References
118
FWCI
22.96
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC. https://app.cochat.ai/papers/10.1016/j.jtho.2018.05.030
The paper
Rolfo, C., Mack, P. C., Scagliotti, G. V., Baas, P., Barlesi, F., Bivona, T. G., Herbst, R. S., Mok, T. S., Peled, N., Pirker, R., Raez, L. E., Reck, M., Riess, J. W., Sequist, L. V., Shepherd, F. A., Sholl, L. M., Tan, D. S. W., Wakelee, H. A., Wistuba, I. I., . . . Gandara, D. R. (2018). Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2018.05.030

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.